MODURETIC 5-50 (amiloride hydrochloride; hydrochlorothiazide) by Merck & Co.. Approved for those patients with hypertension, congestive heart failure, other kaliuretic diuretics are used alone and 3 more indications. First approved in 1981.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
MODURETIC 5-50 is a fixed-dose oral combination of amiloride hydrochloride (potassium-sparing diuretic) and hydrochlorothiazide (thiazide diuretic) indicated for hypertension and congestive heart failure. The drug combines two diuretic mechanisms: amiloride reduces potassium loss by blocking sodium reabsorption in the distal tubule, while hydrochlorothiazide increases sodium and chloride excretion. It is designed for patients where maintenance of normal serum potassium levels is clinically important.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating transition from growth to defensive positioning and likely reduced commercial team size.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on MODURETIC 5-50 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Zero linked job postings indicate minimal active hiring on this brand, consistent with LOE approaching phase. Career opportunities are limited to defensive positioning, generic transition planning, and managed care negotiations. Working on MODURETIC typically involves managing decline and protecting pricing rather than growth or innovation.